Table 3.
Stratified analysis of HLA rs2856718 among persistent infection, spontaneous clearance and control group.
| Supgroups (Genotypes) | Group A n (%) | Group B n (%) | Group C n (%) | OR (95% CI) a | p a′ | OR (95% CI) b | p b | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TT | TC | CC | TT | TC | CC | TT | TC | CC | The outcome: HCV susceptibility | The outcome: HCV clearance | |||
| Age | |||||||||||||
| ≤40 | 37 (27.6) | 75 (56.0) | 22 (16.4) | 20 (30.8) | 30 (46.2) | 15 (23.1) | 69 (24.0) | 153 (53.1) | 66 (22.9) | 0.886 (0.670–1.171) | 0.393 | 0.943 (0.604–1.474) | 0.798 |
| >40 | 71 (31.1) | 104 (45.6) | 53 (23.2) | 49 (38.9) | 57 (45.2) | 20 (15.9) | 186 (27.8) | 349 (52.2) | 133 (19.9) | 0.858 (0.710–1.037) | 0.112 | 1.188 (0.859–1.644) | 0.297 |
| Gender | |||||||||||||
| Male | 64 (31.8) | 102 (50.7) | 35 (17.4) | 39 (35.8) | 49 (45.0) | 21 (19.3) | 135 (25.9) | 286 (54.8) | 101 (19.3) | 0.778 (0.627–0.966) | 0.023 | 0.958 (0.678–1.354) | 0.807 |
| Female | 44 (27.3) | 77 (47.8) | 40 (24.8) | 30 (36.6) | 38 (46.3) | 14 (17.1) | 120 (27.6) | 216 (49.8) | 98 (22.6) | 0.945 (0.754–1.184) | 0.621 | 1.295 (0.860–1.950) | 0.216 |
| Routes of infection | |||||||||||||
| Drug use | 36 (24.3) | 76 (51.4) | 36 (24.3) | 12 (35.3) | 15 (44.1) | 7 (20.6) | 62 (25.9) | 125 (52.3) | 52 (21.8) | 1.021 (0.773–1.348) | 0.883 | 1.363 (0.792–2.347) | 0.264 |
| Hemodialysis | 32 (43.8) | 26 (35.6) | 15 (20.5) | 35 (39.8) | 37 (42.0) | 16 (18.2) | 144 (26.5) | 283 (52.1) | 116 (21.4) | 0.713 (0.552–0.921) | 0.010 | 1.046 (0.682–1.605) | 0.836 |
| PDD | 40 (28.4) | 77 (54.6) | 24 (17.0) | 22 (31.9) | 35 (50.7) | 12 (17.4) | 49 (28.2) | 94 (54.0) | 31 (17.8) | 0.988 (0.726–1.343) | 0.937 | 1.031 (0.657–1.620) | 0.894 |
| HCV genotypes | |||||||||||||
| 1 | 69 (29.9) | 120 (51.9) | 42 (18.2) | 45 (40.2) | 49 (43.8) | 18 (16.1) | – | – | – | – | – | 1.192 (0.847–1.678) | 0.314 |
| Non-1 | 14 (27.5) | 22 (43.1) | 15 (29.4) | 13 (25.0) | 25 (48.1) | 14 (26.9) | – | – | – | – | – | 0.980 (0.558–1.721) | 0.943 |
| Mixed | 25 (31.3) | 37 (46.3) | 18 (22.5) | 11 (40.7) | 13 (48.1) | 3 (11.1) | – | – | – | – | – | 1.292 (0.656–2.545) | 0.459 |
Group A: HCV persistent carriers; Group B: HCV natural clearance subjects; Group C: Healthy controls; Group (A + B): HCV-infected patients. Non-1: genotype 2, 3 and unknown; Mixed: co-infected with genotype 1, 2 and 3; HD: hemodialysis; PDD: paid blood donation. a The p value, odds ratio (OR), 95% confidence intervals (CI) of Group (A + B) versus Group C were calculated on the basis of the logistic regression model, adjusted by gender, age, route of infection, and/or viral genotype; b The p value, odds ratio (OR), 95% confidence intervals (CI) of Group A versus Group B were calculated on the basis of the logistic regression model, adjusted by gender, age, route of infection, and/or viral genotype. Bold type indicates statistically significant results.